The Journal of Antimicrobial Chemotherapy
Overview
The Journal of Antimicrobial Chemotherapy is a renowned scientific journal that publishes cutting-edge research on the development, evaluation, and clinical application of antimicrobial agents. With a focus on combating infectious diseases, this journal provides a platform for researchers and clinicians to share their findings, advancements, and insights in the field of antimicrobial chemotherapy.
Details
Details
Abbr.
J Antimicrob Chemother
Publisher
Oxford University Press
Start
1975
End
Continuing
Frequency
Monthly
p-ISSN
0305-7453
e-ISSN
1460-2091
Country
United Kingdom
Language
English
Specialty
Infectious Diseases
Metrics
Metrics
h-index / Ranks: 534
221
SJR / Ranks: 2572
1271
CiteScore / Ranks: 1714
9.20
JIF / Ranks: 1476
5.2
Recent Articles
1.
Bavaro D, Accurso G, Corcione S, Vena A, Schenone M, Diella L, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40088112
Background: Pseudomonas aeruginosa bloodstream infections (Pa-BSIs) are still a major cause of mortality in ICUs, posing many treatment uncertainties. Methods: This multicentre, retrospective study analysed data from 14 Italian hospitals,...
2.
Morrissey C
J Antimicrob Chemother
. 2025 Mar;
80(Supplement_1):i17-i39.
PMID: 40085540
Invasive fungal infection (IFI) due to moulds other than Aspergillus are a significant cause of morbidity and mortality. Non-Aspergillus mould (NAM) infections appear to be on the increase due to...
3.
Pagano L, Fernandez O
J Antimicrob Chemother
. 2025 Mar;
80(Supplement_1):i2-i8.
PMID: 40085539
Fungal diseases are of growing clinical concern in human medicine as the result of changes in the epidemiology, diversity in clinical presentation, emergence of new pathogens, difficulties in diagnosis and...
4.
Donovan F, Fernandez O, Bains G, DiPompo L
J Antimicrob Chemother
. 2025 Mar;
80(Supplement_1):i40-i49.
PMID: 40085538
Coccidioidomycosis (CM) has been a recognized disease for about 130 years. The organisms (Coccidioides spp. fungi) inhabit desert soil in the southwestern USA, Mexico, and parts of Central and South...
5.
Arendrup M, Cordonnier C
J Antimicrob Chemother
. 2025 Mar;
80(Supplement_1):i9-i16.
PMID: 40085537
Despite notable progress, the management of invasive aspergillosis (IA) remains challenging and treatment failures are common. The final patient outcome is subject to multiple factors including the host (the severity...
6.
Hurley J, Martinez E
J Antimicrob Chemother
. 2025 Mar;
80(Supplement_1):i1.
PMID: 40085536
No abstract available.
7.
Wang B, Wang N, Yu Z, Zhang J
J Antimicrob Chemother
. 2025 Mar;
PMID: 40084823
Background: This study aims to explore effective interventions and observation indicators for reducing antibiotic use in neonates through quality improvement (QI) methods, while quantitatively analysing whether these methods increase the...
8.
Wu S, Zhang L, Luo X, Lin C, Wan P, Huang H, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40079279
Objectives: To evaluate the in vitro and in vivo antimicrobial activity of pleuromutilin derivatives modified with C14 side-chain against Streptococcus suis. Methods: To determine the minimum inhibitory concentrations (MICs) of...
9.
Ngoc Nguyen O, Amin D, Bennett J, Hetlevik O, Malik S, Tout A, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40079276
Introduction: Large language models (LLMs) are becoming ubiquitous and widely implemented. LLMs could also be used for diagnosis and treatment. National antibiotic prescribing guidelines are customized and informed by local...
10.
Singh N, Dangi B, Johnson J, Louie A, Karunanidhi A, Curry B, et al.
J Antimicrob Chemother
. 2025 Mar;
PMID: 40079270
Background: Mycobacterium abscessus is an important cause of pulmonary infections, particularly among people with cystic fibrosis. Current treatment options for M. abscessus are suboptimal. Apramycin is a promising alternative aminoglycoside...